Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?
No abstract is available for this record.
Bibliographic context
- Journal
- Unknown
- Date
- 2023-05-02
- Source
- Europe PMC
- PubMed
- 37139585
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.Australian & New Zealand Journal of Psychiatry · 2021-03-20Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia.The Medical Journal of Australia · 2017-05-31A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-03-02Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscapeAustralian & New Zealand Journal of Psychiatry · 2025-12-16The occurrence of the psychotomimetic agent psilocybin in an Australian agaric, Psilocybe subaeruginosaAustralian Journal of Chemistry · 1970-03-31Corrigendum to: “Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape”Australian & New Zealand Journal of Psychiatry · 2026-05-17Psilocybin-assisted therapy for depression: How do we advance the field?Australian & New Zealand Journal of Psychiatry · 2019-11-21A fungus among us: investigating queensland’s largest magic mushroom growing operationAustralian Journal of Forensic Sciences · 2026-03-15